In contrast to the post-translational regulation of PD-L1 by glycosylase inhibitors [40], our previous study showed that NR4A1 regulates expression of PD-L1 in breast cancer cell lines and CDIM/NR4A1 antagonists decrease expression of this gene [23]. This evidence concerns the gene NR4A1 and breast carcinoma.